Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.

Literature DB >> 6223692

Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.

R Markkula, H Repo, M Leirisalo, C Blomqvist, I Elomaa.

Abstract

Immune function was studied in normocalcemic breast cancer patients with bone metastases treated with either dichloromethylene diphosphonate (Cl2MDP) or placebo. The results showed no significant difference between the two patient groups. This suggests that Cl2MDP does not markedly impair the host's defense mechanisms, and in this respect can be safely used in the treatment of patients with resorptive bone disease.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1983 PMID： 6223692 DOI： 10.1007/bf00199709

Source DB: PubMed Journal: Cancer Immunol Immunother ISSN： 0340-7004 Impact factor: 6.968

22 in total

1. Abnormal monocyte chemotactic response in cancer patients.

Authors: D A Boetcher; E J Leonard
Journal: J Natl Cancer Inst Date: 1974-04 Impact factor: 13.506

2. Diphosphonates: aimed in a chemical sense.

Authors:
Journal: Lancet Date: 1981-12-12 Impact factor: 79.321

3. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation.

Authors: E de Vries; J P van der Weij; C J van der Veen; H C van Paassen; M J Jager; H P Sleeboom; O L Bijvoet; A Cats
Journal: Immunology Date: 1982-09 Impact factor: 7.397

Review 1. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors: H Fleisch
Journal: Drugs Date: 1991-12 Impact factor: 9.546

1 in total

Effect of dichloromethylene diphosphonate (Cl2MDP) on immune function in breast cancer patients with bone metastases.

1. Abnormal monocyte chemotactic response in cancer patients.

2. Diphosphonates: aimed in a chemical sense.

3. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation.

Review 4. Experimental basis for the clinical use of diphosphonates in Paget's disease of bone.

5. Long-term therapy of Paget's disease of bone with EHDP.

Review 6. The role of T cell subsets and Ia antigens in delayed-type hypersensitivity.

7. Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal.

8. Use of etidronate (EHDP) in Paget's disease of bone.

9. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.

10. Function of neutrophils in preleukaemia.

Review 1. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.